<DOC>
	<DOCNO>NCT00401011</DOCNO>
	<brief_summary>This phase I/II study perifosine combination bortezomib—with without dexamethasone—for patient relapse refractory multiple myeloma previously treat bortezomib . The current protocol enroll patient relapse refractory multiple myeloma previously treat bortezomib . The patient treat perifosine , 50 mg 100 mg qhs , combination bortezomib determine preliminary evidence addition perifosine improve outcome patient . Previous treatment perifosine allow study . Patients progress treatment perifosine bortezomib receive dexamethasone 20 mg day 1 , 2 , 4 , 5 , 8 , 9 , 11 , 12 , 15 , 16 , 18 , 19 21-day cycle addition bortezomib perifosine .</brief_summary>
	<brief_title>Safety &amp; Efficacy Study Perifosine + Bortezomib +/- Dexamethasone Multiple Myeloma Patients</brief_title>
	<detailed_description>The primary objective phase I portion determine maximum tolerate dose perifosine combination bortezomib patient previously treat bortezomib . All patient receive daily perifosine qhs food . In initial phase I study , 3 patient enter specified combination perifosine bortezomib cohort . If dose-limiting toxicity observe , three additional patient enter cohort 4 - full dose bortezomib ( 1.3 mg/m2 day 1 , 4 , 8 11 every 3 week ) . If dose tolerate used phase II study , otherwise intermediate dose 1 mg/m2 day 1 , 4 , 8 , 11 every 3 week employ . The phase II study use maximum tolerate dose bortezomib perifosine . The primary objective phase II portion determine response rate ( combine CR + PR + MR ) follow treatment perifosine + bortezomib patient multiple myeloma relapse follow initial front-line therapy , refractory recent therapy , previously treat bortezomib . The secondary objective phase II portion ; 1 . To assess safety tolerability perifosine combination bortezomib—with without dexamethasone—in patient multiple myeloma . 2 . To obtain correlative data patient multiple myeloma treat perifosine combination bortezomib—with without dexamethasone ( NOTE Centers may choose participate correlative study ) .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Subject previously diagnose multiple myeloma base standard diagnostic criterion , follow . Major criterion : Plasmacytomas tissue biopsy . Bone marrow plasmacytosis ( &gt; 30 % plasma cell ) . Monoclonal immunoglobulin spike serum electrophoresis immunoglobulin G ( IgG ) &gt; 3.5 g/dL immunoglobulin A ( IgA ) &gt; 2.0 g/dL ; kappa lambda light chain excretion &gt; 1 g/day 24 hour urine protein electrophoresis . Minor criterion : Bone marrow plasmacytosis ( 10 30 % plasma cell ) . Monoclonal immunoglobulin present less magnitude give major criterion . Lytic bone lesion . Normal IgM &lt; 50 mg/dL , IgA &lt; 100 mg/dL IgG &lt; 600 mg/dL . 2 . Any following set criteria confirm diagnosis multiple myeloma : 3 . Any two major criterion . 4 . Major criterion 1 plus minor criterion b , c , d. 5 . Major criterion 3 plus minor criterion c. 6 . Minor criterion , b , c , b , d. 7 . Patients must relapse refractory disease ( refractory define progression treatment within 60 day completion treatment ) . 8 . Patients must previously treat bortezomib . Patients may receive prior perifosine . 9 . Age &gt; = 18 year time signing informed consent document . 10 . All necessary baseline study determine eligibility must obtain within 14 day prior enrollment . ( Pregnancy test must within 7 day woman childbearing potential . ) 11 . Subject ECOG ( Zubrod ) performance status 0 2 . 12 . Subject must able adhere study visit schedule protocol requirement . 13 . Subject must understand voluntarily sign informed consent document . 14 . Women childbearing potential ( WCBP ) — must negative serum urine pregnancy test within 72 hour prior enrollment . In addition , sexually active WCBP male patient must agree use adequate contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) throughout study . 1 . Renal insufficiency ( serum creatinine level &gt; 3 mg/dL ) . 2 . Patients present either ALT AST &gt; = 2.5 X upper limit normal ( ULN ) and/or patient bilirubin &gt; = 1.5 X ULN . 3 . History allergic reaction attribute compound similar chemical biologic composition perifosine ( miltefosine edelfosine ) . 4 . Concomitant medication include corticosteroid ( except indicate medical condition 100 mg hydrocortisone equivalent premedication administration certain medication blood product ) , chemotherapy , therapy may active myeloma within 2 week prior Cycle 1 Day 1 . Nitrosoureas must discontinue 6 week prior Cycle 1 Day 1 . 5 . Subjects hemoglobin &lt; 8.0 g/dL . 6 . Subjects absolute neutrophil count ( ANC ) &lt; = 500 cells/mm3 . 7 . Peripheral neuropathy grade 3 great . Patients painful grade 2 neuropathy also exclude . 8 . Subjects evidence mucosal internal bleeding and/or platelet refractory ( i.e. , unable maintain platelet count &gt; = 50,000 cells/mm3 ) . 9 . Previous history intolerance bortezomib perifosine . 10 . Any condition , include laboratory abnormality , opinion investigator place subject unacceptable risk he/she participate study . 11 . WCBP pregnant breastfeed men woman use adequate contraception . 12 . Plasma cell leukemia time study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Perifosine</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Dexamethasone</keyword>
	<keyword>Relapsed Refractory Multiple Myeloma</keyword>
</DOC>